Glenmark Pharmaceuticals has announced the launch of Vancomycin Hydrochloride for Injection USP in the U.S. market in two strengths: 500 mg/vial and 1 g/vial, through its U.S. arm, Glenmark Pharmaceuticals Inc., USA.

The product is bioequivalent and therapeutically equivalent to the reference listed drug by Fresenius Kabi USA, LLC.

According to IQVIA data for the 12-month period ending March 2026, the Vancomycin Hydrochloride for Injection USP market recorded annual sales of approximately $37.9 million in the U.S.

Commenting on the launch, Marc Kikuchi, President & Business Head, North America said, “The launch of Vancomycin Hydrochloride for Injection USP, 500 mg/vial and 1 g/vial reflects Glenmark’s continued commitment to expanding access to quality, affordable medicines in the U.S. It also strengthens our injectable portfolio and reinforces our focus on delivering reliable treatment options to healthcare providers and patients.”